KIMBERLY ZIEFEL: Open Payments
NPI 1285295006 · ASHEBORO, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,093 in 60 payments from 21 companies in 2025. Trend: 2023 $42 · 2024 $23 · 2025 $1,093
Food & beverage: $1,093
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $217 |
| Novo Nordisk Inc | 9 | $162 |
| AstraZeneca Pharmaceuticals LP | 5 | $100 |
| Lilly USA, LLC | 4 | $79 |
| Otsuka America Pharmaceutical, Inc. | 4 | $75 |
| Esperion Therapeutics, Inc. | 3 | $57 |
| Lundbeck LLC | 3 | $50 |
| Vanda Pharmaceuticals Inc. | 2 | $42 |
| GlaxoSmithKline, LLC. | 2 | $38 |
| Biogen, Inc. | 2 | $35 |
Products named: VRAYLAR, Ozempic, REXULTI, NEXLETOL, QULIPTA, Leqembi, JARDIANCE, MOUNJARO.
Industry payments across NC — which companies pay providers there.
